Amgen tops Q2 expectations; tightens FY22 revenue guidance
Amgen press release  (NASDAQ:AMGN): Q2  Non-GAAP EPS of $4.65  beats by $0.32.
Revenue of $6.6B (+1.1% Y/Y)  beats by $70M.
Volumes grew double-digits for a number of products including RepathaÂ (evolocumab), ProliaÂ (denosumab), LUMAKRAS/LUMYKRAS (sotorasib) and EVENITYÂ (romosozumab-aqqg).
2022 total revenues guidance revised to $25.5B-26.4B from prior outlook of $25.4B-26.5B vs. consensus of $26.22B; EPS guidance revised to $11.01-12.15 on a GAAP basis, and reaffirmed at $17.00-18.00 on a non-GAAP basisÂ from prior outlook of $17.00-18.00 vs. consensus of $17.40.